Menu
← Oncology Approval Tracker
FDA DECISION ·
Tagrisso + platinum chemotherapy
osimertinib with pemetrexed and platinum chemotherapy · AstraZeneca
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
First-line treatment of locally advanced or metastatic non-small cell lung cancer with an FDA test-confirmed EGFR exon 19 deletion or exon 21 L858R mutation, using osimertinib with pemetrexed and platinum chemotherapy.
LAMPGEN ANALYSIS
Why it matters
The label added chemotherapy to frontline osimertinib as an option for common EGFR variants.
What research teams should watch
Coordinate oral and infusion treatment and record induction, maintenance, cumulative exposure and reasons for modification.
PRIMARY RECORDS